Evidence map›Paper›PMID 41792052›Full record

Observational studyInternational journal of cancer2026

Real-world progression-free survival and overall survival in patients with HR

Peter A Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke-Heckenkamp, Diana Lüftner and 11 more

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Peter A FaschingDepartment of Obstetrics and Gynecology, University Hospital Erlangen, Erlangen, Germany.
Cosima BruckerDepartment of Obstetrics and Gynecology, Klinikum Nürnberg Nord, Paracelsus Medical University, Nürnberg, Germany.
Thomas DeckerOncology Ravensburg, Ravensburg, Germany.ORCID https://orcid.org/0000-0003-3814-8775
Anne EngelWinicker Norimed GmbH, Nürnberg, Germany.
Thomas GöhlerOnkozentrum Dresden/Freiberg, Dresden, Germany.
Christian JackischEvangelische Kliniken Essen Mitte gGmbH (KEM), Essen, Germany.
Jan JanssenMedizinische Studiengesellschaft Nord-West GmbH, Westerstede, Germany.
Andreas KöhlerPractice for Hematology and Oncology, Langen, Germany.
Kerstin Lüdtke-HeckenkampDepartment of Oncology and Hematology, Niels-Stensen Kliniken, Georgsmarienhütte, Germany.
Diana LüftnerImmanuel Hospital Märkische Schweiz, Buckow & Immanuel Campus Rüdersdorf, Medical University of Brandenburg Theodor Fontane, Rüdersdorf bei Berlin, Germany.
Frederik MarméDepartment of Gynecology and Obstetrics, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Marion van MackelenberghDepartment of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Kiel, Germany.
Beate RautenbergMedical Center-University of Freiburg, Freiburg, Germany.
Marcus SchmidtDepartment of Gynecology and Obstetrics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Rudolf WeideInstitut für Versorgungsforschung in der Onkologie, Koblenz, Germany.
Pauline WimbergerDepartment of Gynecology and Obstetrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, and NCT Dresden, Dresden, Germany.
Elena KisseleffNovartis Pharma GmbH, Nürnberg, Germany.
Christina PfisterNovartis Pharma GmbH, Nürnberg, Germany.
Claudia QuieringNovartis Pharma GmbH, Nürnberg, Germany.
Christian RoosNovartis Pharma GmbH, Nürnberg, Germany.
Achim WöckelDepartment of Obstetrics and Gynecology, University Hospital Würzburg, Würzburg, Germany.

Funding

Novartis Pharma GmbH, Nuremberg, Germany
6 · The paper itself

Abstract

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are the preferred choice for first-line treatment of patients with HR

Indexed as

AminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsPurinesAdultAgedAromatase InhibitorsErb-b2 Receptor Tyrosine KinasesFemaleFulvestrantHumansMiddle AgedProgression-Free SurvivalReceptors, EstrogenReceptors, ProgesteroneAminopyridinesAromatase InhibitorsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFulvestrantPurinesReceptors, EstrogenReceptors, ProgesteroneribociclibCDK4/6 inhibitorsmetastatic breast cancerobservational studyoverall survivalribociclib

Identifiers

PMID41792052
PMCPMC13139987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.